Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy
Aasha I. Hoogland(Moffitt Cancer Center), Heather Jim(Moffitt Cancer Center), Aleksandr Lazaryan(Moffitt Cancer Center), Kelly A. Hyland(University of South Florida), Shannon M. Christy(University of South Florida), Margaret Booth‐Jones(Moffitt Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Bijal Shah(Boston College), Anna Barata(Massachusetts General Hospital), Anuhya Kommalapati(University of South Carolina), Reena Jayani(Vanderbilt University Medical Center), Jennifer M. Logue(Moffitt Cancer Center), Ashley M. Nelson(Harvard University), Hailey W. Bulls(Moffitt Cancer Center), Sarah L. Eisel(Moffitt Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Sepideh Mokhtari(Moffitt Cancer Center), Brent J. Small(University of North Carolina at Chapel Hill), Brian W. James(University of South Florida), Michael D. Jain(Moffitt Cancer Center)
Cited by 44
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k